Compare AstraZeneca plc (AZN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Novartis AG — how do they compare? AstraZeneca plc trades at $158.56 (market cap $250.84B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| AZN | NVS | |
|---|---|---|
Market Cap | $250.84B | $298.18B |
Sector | Health | Health |
52-Week High | $209.48 | $168.62 |
52-Week Low | $147.06 | $119.31 |
Enterprise Value | $278.12B | $339.50B |
Dividend Yield | 1.97% | 3.02% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
